Bayer ponders $1.1 billion portfolio sale to fund Monsanto acquisition
pharmafile | September 12, 2016 | News story | Business Services, Manufacturing and Production, Sales and Marketing | Bayer, acquisition, monsanto
In the latest development in the Bayer-Monsanto saga, the German drugmaker has enlisted the aid of global financial services firm JPMorgan Chase to assess possible options with its dermatology unit, the sale of which could reportedly generate over $1.1 billion for the company.
The firm’s dermatology portfolio includes its eczema therapy Desonate and its rosacea treatment Finacea, and it hopes the funds generated from their sale could help give the extra push needed to secure the acquisition of the agricultural giant.
According to Bloomberg sources, the portfolio could prove particularly attractive to a range of buyers including Nestle’s Galderma, Allergan or Spain’s Almirall, the latter of whom has made it no secret it is on the hunt for dermatology products, with CEO Eduardo Sanchiz having gone on record as eyeing certain Valeant offerings.
This development comes following Bayer’s latest effort last week to secure Monsanto as it raised its valuation of the firm to $56 billion.
Matt Fellows
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Brenntag acquires mcePharma to expand GMP capabilities in biopharma services
Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries …

Curium Pharma announces acquisition of Monrol
Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine …






